Amneal acquires Kashiv BioSciences, creating global biosimilars leaderThe transaction brings together complementary R&D, manufacturing and commercial capabilities, positioning the company to accelerate biosimilar launches, expand patient access and capitalise on growing biologic loss-of-exclusivity opportunitiesBy Telangana Today Updated On - 10 August 2026, 11:45 PMChirag Patel, Co-Founder & Co-CEO, Amneal PharmaceuticalsBridgewater: Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NASDAQ: AMRX) today announced the completion of its acquisition of Kashiv BioSciences, LLC (“Kashiv”), creating a fully integrated global biosimilars leader with end-to-end capabilities across research, development, manufacturing and commercialisation. “The completion of this acquisition marks a pivotal step in Amneal’s strategy to become America’s #1 Affordable Medicines company,” said Chirag Patel, Co-Founder and Co-Chief Executive Officer. The transaction provides Amneal access to the global biosimilars market, with more than $300 billion in projected global biologics loss of exclusivity over the next decade. Integration and next stepsThe transaction builds on a relationship between Amneal and Kashiv spanning more than a decade, providing a strong foundation for integration. Kashiv BioSciences, LLC in the U.S., together with its subsidiaries in India (collectively, “Kashiv BioSciences”), operates with robust infrastructure and highly skilled teams that provide global R&D, clinical, manufacturing, regulatory and IP capabilities.